NCT02039817已完成1 期
An Open-Label Pharmacokinetic and Pharmacodynamic Study of a Single Dose of IDN-6556 in Subjects With Severe Renal Impairment and in Matched Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 2
- 主要终点
- Cmax
研究概览
简要总结
This is an open-label, parallel-group study to compare the pharmacokinetics and pharmacodynamics of IDN-6556 following a single 50 mg oral dose of IDN-6556 in subjects with severe renal impairment and matched healthy volunteers with normal renal function.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •All Subjects:
- •Male or female subjects 18 - 75 years of age, able to provide written informed consent, understand and comply with all scheduled visits, and other requirements of the study
- •Body mass index (BMI) 18.0 - 40.0 kg/m2 and body weight >50 kg
- •Willingness to utilize two reliable forms of contraception (for both males and females of childbearing potential) from screening to one month after the last dose of study drug
- •Matched Healthy Volunteers:
- •Medically healthy as determined by the Investigator
- •Screening creatinine clearance ≥90 mL/min using the Cockcroft-Gault equation
- •Supine blood pressure ≤145/90 mmHg
- •No significant uncontrolled systemic or major illness that, in the opinion of the Investigator, would preclude the subject from participating in and completing the study
- •Demographically comparable to subjects with severe renal impairment as follows:
- •Mean body weight within ±10 kg
- •Mean age within ±5 years
- •Similar gender ratio
- •Severe Renal Impaired Subjects:
- •Screening creatinine clearance (CLCR) <30 mL/min using the Cockcroft-Gault equation
- •Supine blood pressure ≤170/110 mmHg
- •Documented renal impairment indicated by reduced creatinine clearance within 12 months of screening or longer
- •Stable renal function as evidenced by ≤30% difference in two measurements of creatinine clearance on two separate occasions separated by at least 28 days with one measurement being the value at screening.
排除标准
- •History of renal trasplant
- •Acute renal failure
- •Subjects undergoing any method of dialysis or hemofiltration
- •Evidence or history of clinically significant uncontrolled hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)
- •Disorders or surgery of the gastrointestinal tract which may interfere with drug absorption or may otherwise influence the pharmacokinetics of the investigational medicinal product (e.g., inflammatory bowel disease, resections of the small or large intestine, etc.)
- •History of febrile illness within 5 days prior to dosing
- •Evidence of clinically significant liver disease or liver damage (e.g., hepatitis B or C, autoimmune hepatitis, primary biliary cirrhosis, non-alcoholic fatty liver disease, elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) that is considered clinically significant by the Investigator, etc.)
- •Known infection with human immunodeficiency virus (HIV) upon serological testing
- •History or presence of clinically concerning cardiac arrhythmias, or prolongation of Screening (pre-treatment) QT or QTc interval of >480 milliseconds (msec) for subjects with severe renal impairment or >450 msec for matched healthy volunteers
- •Subjects with active or history of malignancies other than curatively treated skin cancer (basal cell or squamous cell carcinomas)
研究组 & 干预措施
Healthy Volunteers
Experimental
All subjects receive a single 50 mg oral dose of IDN-6556
干预措施: IDN-6556 (Drug)
Severe Renal Impairment
Experimental
All subjects receive a single 50 mg oral dose of IDN-6556
干预措施: IDN-6556 (Drug)
结局指标
主要结局
Cmax
时间窗: 48 hours
Maximum concentration (Cmax)
AUC
时间窗: 48 hours
Area under the plasma concentration curve (AUC) parameters include AUC0-12, AUCinf, AUClast
次要结局
- Levels of cCK18(48 hours)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy VolunteersHepatic ImpairmentLiver DiseasesDigestive System DiseasesNCT02121860Conatus Pharmaceuticals Inc.37
已完成
1 期
Study of Pharmacokinetics, Pharmacodynamics and Safety Assessment of GNR-044 (JSC GENERIUM, Russia) and Xolair®Healthy VolunteersNCT04601389AO GENERIUM84
已完成
1 期
A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Healthy Male SubjectsBioavailability StudyNCT03334084argenx40
已完成
1 期
Comparative Study of PK and BE of VM-1500FDC (Fixed-dose Combination) and Elpida® With Truvada® сo-administrated 1 Daily Fasting in Healthy SubjectsHIV-1-infectionNCT03706924Viriom140
已完成
2 期
Open Label Arimidex in GynecomastiaGynecomastiaNCT00241436AstraZeneca35